James M. Hinson
Corporate Officer/Principal presso Unicorn Pharma Consulting, Inc.
Posizioni attive di James M. Hinson
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Unicorn Pharma Consulting, Inc. | Corporate Officer/Principal | 06/11/2009 | - |
Storia della carriera di James M. Hinson
Precedenti posizioni note di James M. Hinson
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Aldagen, Inc.
 Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Direttore Tecnico/Scientifico/R&S | 06/11/2009 | - |
| Corporate Officer/Principal | 06/11/2009 | 06/11/2009 |
Formazione di James M. Hinson
| Vanderbilt University | Doctorate Degree |
| University of Missouri | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Settori
| Consumer Services | 3 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Health Technology |
| Unicorn Pharma Consulting, Inc. |
- Borsa valori
- Insiders
- James M. Hinson
- Esperienza
